Stock A8D AB SCIENCE
Add to a list
To use this feature you must be a member
Log inSign up

AB Science Stock Deutsche Boerse AG

Equities

A8D

FR0010557264

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 02:05:37 2024-04-25 am EDT 		5-day change 1st Jan Change
1.818 EUR -6.19% Intraday chart for AB Science -8.37% -49.92%
Apr. 04 AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada MT
Apr. 03 AB Science: reconsideration possible for masitinib in ALS CF

Financials

Sales 2023 * 930K 997K Sales 2024 * 990K 1.06M Capitalization 96.21M 103M
Net income 2023 * -19M -20.37M Net income 2024 * -18M -19.3M EV / Sales 2023 * 103 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 97.2 x
P/E ratio 2023 *
-4.96 x
P/E ratio 2024 *
-5.23 x
Employees 89
Yield 2023 *
-
Yield 2024 *
-
Free-Float 66.05%
More Fundamentals * Assessed data

Chart AB Science

Dynamic Chart

Latest news about AB Science

AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada MT
AB Science: reconsideration possible for masitinib in ALS CF
AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS CI
AB Science: encouraging results for masitinib CF
Transcript : AB Science S.A. - Special Call
AB Science: share price falls, negative opinion in Canada CF
AB Science: share price falls, CHMP verdict postponed CF
AB Science: medical use patent for masitinib CF
AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis CI
Transcript : AB Science S.A. - Special Call
AB Science: project selected for public funding CF
AB Science S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Global markets live: Kingfisher, Tesla, Ulta Beauty, Amazon, Target... Our Logo
AB Science: decision in ALS expected in early 2024 CF
AB Science Expects European Marketing Authorization for Rare Neurological Disease Drug in Early 2024 MT
More news

Latest transcript on AB Science

Logo AB Science
AB Science S.A. - Special Call
More transcripts

Analyst Recommendations on AB Science

AB Science : Masitinib Treatment Against Pancreatic Cancer Boosts Survival Rates MT
SCIENCE : AB Science: Chardan Capital Markets initiates coverage with a BUY recommendation on AB Science and a target price of €30 GL
More recommendations

Press releases AB Science

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS GL
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease GL
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease AQ
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development GL
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development AQ
More press releases

News in other languages on AB Science

AB Science : plus forte baisse du SRD à la clôture du mercredi 17 avril 2024 -
Powell garde le pouce levé
En Direct des Marchés : Sanofi, Kering, Saint-Gobain, Accor, Gaussin, Solutions 30, Apple, Nvidia...
AB Science : réexamen possible pour le masitinib dans la SLA
AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA
More news

Quotes and Performance

1 day-6.19%
1 week-8.37%
Current month-28.28%
1 month-27.86%
3 months-48.79%
6 months-21.30%
Current year-49.92%
More quotes

Highs and lows

1 week
1.82
Extreme 1.818
1.95
1 month
1.82
Extreme 1.818
2.56
Current year
1.82
Extreme 1.818
3.71
1 year
1.82
Extreme 1.818
6.36
3 years
1.82
Extreme 1.818
16.30
5 years
1.82
Extreme 1.818
20.10
10 years
1.82
Extreme 1.818
20.10
More quotes

Managers and Directors - AB Science

Managers TitleAgeSince
Alain Moussy CEO
 Chief Executive Officer - 01-07-10
Laurent Guy DFI
 Director of Finance/CFO - 01-12-31
Christian Fassotte CTO
 Chief Tech/Sci/R&D Officer - 18-03-31
Members of the board TitleAgeSince
Alain Moussy CEO
 Chief Executive Officer - 01-07-10
Patrick Moussy BRD
 Director/Board Member - 01-07-10
Cécile de Guillebon BRD
 Director/Board Member 62 21-06-26
More insiders

Quotes

Date Price Change
24-04-25 1.818 -6.19%
24-04-24 1.938 -0.82%
24-04-23 1.954 +1.35%
24-04-22 1.928 +0.94%
24-04-19 1.91 -3.73%

Delayed Quote Deutsche Boerse AG, April 25, 2024 at 02:05 am EDT

More quotes

Company Profile

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.
Sector
Pharmaceuticals
Calendar
2024-04-29 - Q4 2023 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.884 EUR
Average target price
6.895 EUR
Spread / Average Target
+265.98%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
MERCK KGAA Stock Merck KGaA
+4.16% 70.78B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+11.20% 9.15B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-17.03% 4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+37.51% 4.22B
YUHAN CORPORATION Stock Yuhan Corporation
+3.92% 3.92B
INDIVIOR PLC Stock Indivior PLC
+18.14% 2.55B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-24.13% 2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.70% 2.24B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+9.09% 1.92B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AB Stock
  4. A8D Stock